{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T04:59:06Z","timestamp":1782017946568,"version":"3.54.5"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To demonstrate the clinical features and prognostic impact of cyclin D1 positivity in patients with amyloid light chain amyloidosis (AL).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We consecutively included 71 patients diagnosed with AL with cyclin D1 positivity between February 2008 and January 2022. t(11;14) was examined through interphase fluorescence in situ hybridization using bone marrow cells.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The median age of the patients was 73 years, and 53.5% were male. The underlying diseases included symptomatic multiple myeloma, smoldering multiple myeloma, Waldenstr\u00f6m macroglobulinemia, and monoclonal gammopathy of undetermined significance, representing 33.8%, 26.8%, 2.8%, and 36.6%, respectively. The prevalence of cyclin D1 and t(11;14) was 38.0% and 34.7%, respectively. Higher frequency of light chain paraprotein type was seen in cyclin D1\u2013positive patients with AL than in cyclin D1\u2013negative patients (70.4% vs 18.2%). The median overall survival (OS) of patients with AL with and without cyclin D1 expression was 18.9 months and 73.1 months, respectively (P = .019). Early death occurred in 44.4% of cyclin D1\u2013positive patients and 31.8% of cyclin D1\u2013negative patients. Moreover, 83.3% of cyclin D1\u2013positive patients and 21.4% of cyclin D1\u2013negative patients died of cardiac causes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Cyclin D1 immunohistochemistry accurately identified patients with t(11;14). Cyclin D1\u2013positive patients had significantly inferior OS compared with cyclin D1\u2013negative patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajcp\/aqad013","type":"journal-article","created":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T17:56:01Z","timestamp":1679334961000},"page":"157-163","source":"Crossref","is-referenced-by-count":5,"title":["Clinical Characteristics and Outcomes of Cyclin D1\u2013Positive AL Amyloidosis"],"prefix":"10.1093","volume":"160","author":[{"given":"Takafumi","family":"Tsushima","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Kameda Medical Center , Kamogawa , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6728-3346","authenticated-orcid":false,"given":"Toshiki","family":"Terao","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Kameda Medical Center , Kamogawa , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Narita","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Kameda Medical Center , Kamogawa , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Fukumoto","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Kameda Medical Center , Kamogawa , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Kameda Medical Center , Kamogawa , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Kamura","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Kameda Medical Center , Kamogawa , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Kuzume","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Kameda Medical Center , Kamogawa , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikako","family":"Tabata","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Kameda Medical Center , Kamogawa , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Miura","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Kameda Medical Center , Kamogawa , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Kameda Medical Center , Kamogawa , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8669-9865","authenticated-orcid":false,"given":"Kosei","family":"Matsue","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Kameda Medical Center , Kamogawa , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,20]]},"reference":[{"key":"2023080113003031400_CIT0001","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet."},{"key":"2023080113003031400_CIT0002","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primers."},{"key":"2023080113003031400_CIT0003","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol."},{"key":"2023080113003031400_CIT0004","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood."},{"key":"2023080113003031400_CIT0005","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood."},{"key":"2023080113003031400_CIT0006","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med."},{"key":"2023080113003031400_CIT0007","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood.2019004460","article-title":"Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood."},{"key":"2023080113003031400_CIT0008","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1182\/bloodadvances.2018023200","article-title":"Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma","volume":"2","author":"Bochtler","year":"2018","journal-title":"Blood Adv."},{"key":"2023080113003031400_CIT0009","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3324\/haematol.13369","article-title":"Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis","volume":"94","author":"Bryce","year":"2009","journal-title":"Haematologica."},{"key":"2023080113003031400_CIT0010","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","article-title":"Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens","volume":"33","author":"Bochtler","year":"2015","journal-title":"J Clin Oncol."},{"key":"2023080113003031400_CIT0011","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/13506129.2020.1778461","article-title":"Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen","volume":"27","author":"Dumas","year":"2020","journal-title":"Amyloid"},{"key":"2023080113003031400_CIT0012","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1182\/blood-2015-10-676361","article-title":"Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study","volume":"128","author":"Bochtler","year":"2016","journal-title":"Blood."},{"key":"2023080113003031400_CIT0013","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-020-00397-w","article-title":"Venetoclax induces deep hematologic remissions in t(11;14) relapsed\/refractory AL amyloidosis","volume":"11","author":"Premkumar","year":"2021","journal-title":"Blood Cancer J."},{"key":"2023080113003031400_CIT0014","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1038\/bcj.2015.34","article-title":"Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death","volume":"5","author":"Warsame","year":"2015","journal-title":"Blood Cancer J."},{"key":"2023080113003031400_CIT0015","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1111\/cas.14109","article-title":"Immunohistochemistry for identification of CCND1, NSD2, and MAF gene rearrangements in plasma cell myeloma","volume":"110","author":"Murase","year":"2019","journal-title":"Cancer Sci."},{"key":"2023080113003031400_CIT0016","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/hon.2300","article-title":"Quantification of bone marrow plasma cell infiltration in multiple myeloma: usefulness of bone marrow aspirate clot with CD138 immunohistochemistry","volume":"35","author":"Matsue","year":"2017","journal-title":"Hematol Oncol."},{"key":"2023080113003031400_CIT0017","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/ajh.24236","article-title":"Myeloma today: disease definitions and treatment advances","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Am J Hematol."},{"key":"2023080113003031400_CIT0018","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"2023080113003031400_CIT0019","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/blood-2018-09-825331","article-title":"Toward personalized treatment in multiple myeloma based on molecular characteristics","volume":"133","author":"Pawlyn","year":"2019","journal-title":"Blood."},{"key":"2023080113003031400_CIT0020","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cancergencyto.2006.09.017","article-title":"Frequency and distribution of trisomy 11 in multiple myeloma patients: relation with overexpression of CCND1 and t(11;14)","volume":"173","author":"Guglielmelli","year":"2007","journal-title":"Cancer Genet Cytogenet."},{"key":"2023080113003031400_CIT0021","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/leu.2017.204","article-title":"Natural history of t(11;14) multiple myeloma","volume":"32","author":"Lakshman","year":"2018","journal-title":"Leukemia."},{"key":"2023080113003031400_CIT0022","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/leu.2016.369","article-title":"Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category","volume":"31","author":"Muchtar","year":"2017","journal-title":"Leukemia."},{"key":"2023080113003031400_CIT0023","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.3324\/haematol.2016.163246","article-title":"Lenalidomide\/melphalan\/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up","volume":"102","author":"Hegenbart","year":"2017","journal-title":"Haematologica."},{"key":"2023080113003031400_CIT0024","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood.2019003633","article-title":"Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria","volume":"135","author":"Kimmich","year":"2020","journal-title":"Blood."},{"key":"2023080113003031400_CIT0025","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.3324\/haematol.2016.160721","article-title":"Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis","volume":"102","author":"Granzow","year":"2017","journal-title":"Haematologica."},{"key":"2023080113003031400_CIT0026","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3109\/13506129.2013.854766","article-title":"Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan\/dexamethasone","volume":"21","author":"Bochtler","year":"2014","journal-title":"Amyloid"}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/160\/2\/157\/51016051\/aqad013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/160\/2\/157\/51016051\/aqad013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T13:01:15Z","timestamp":1690894875000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/160\/2\/157\/7081214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,20]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,3,20]]},"published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqad013","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8,1]]},"published":{"date-parts":[[2023,3,20]]}}}